ClinicalTrials.gg
CompletedNCT02121795Updated Mar 12, 2020Results posted

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

A Phase 3 interventional study of FTC/TDF and F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 78 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-12.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
668
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the efficacy of switching from emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) fixed dose combination (FDC) to emtricitabine/tenofovir alafenamide (F/TAF) FDC in HIV-1 positive participants who are virologically suppressed on regimens containing FTC/TDF.

This study will consist of a 96 week double-blind treatment period. After Week 96, all participants will continue on blinded study drug treatment and attend visits every 12 weeks until treatment assignments are unblinded. All participants will return for an unblinding visit and will be given the option to receive open-label F/TAF and attend visits every 12 weeks until F/TAF is commercially available, or the sponsor terminates the F/TAF clinical development program.

02

Conditions studied

  • HIV-1 Infection

Keywords

  • HIV
  • HIV-1 Positive
  • Virologically-suppressed
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
  • Currently receiving antiretroviral regimen containing FTC/TDF in combination with one third agent for ≥ 6 consecutive months prior to screening.
  • Plasma -1 RNA levels \< 50 copies/mL for at least 6 months preceding the screening visit (measured at least twice using the same assay) and not experienced two consecutive HIV-1 RNA above detectable levels after achieving a confirmed (two consecutive) HIV-1 RNA below detectable levels on the current regimen in the past year.
  • Plasma HIV-1 RNA should be \< 50 copies/mL at the screening visit.
  • Normal (ECG)
  • Estimated (eGFR) ≥ 50 mL/min according to the formula for creatinine clearance
  • (AST) and alanine aminotransferase (ALT) ≤ 5 × the (ULN)
  • Total ≤ 1.5 mg/dL, or normal direct bilirubin (individuals with documented Gilbert's syndrome or with Atazanavir-associated hyperbilirubinemia may have total bilirubin up to 5 x ULN)
  • Adequate hematologic function
  • Serum amylase ≤ 5 × ULN
  • Females of must agree to utilize highly effective methods or be non-heterosexually active, or practice abstinence from screening throughout the duration of the study treatment and for 30 days following the last dose of the study drug.
  • Females who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level at screening within the range based on the Central Laboratory reference range.
  • Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing.
  • Males must agree to utilize a highly effective method of contraception during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence from first dose throughout the study period and for 30 days following the last study drug dose.

Key Exclusion Criteria:

  • A new AIDS-defining condition diagnosed within the 30 days prior to screening
  • virus (HCV) antibody positive and HCV RNA detectable
  • Individuals experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, etc.)
  • Individuals receiving ongoing treatment with bisphosphonate to treat bone disease (eg, osteoporosis)
  • Females who are breastfeeding
  • Positive serum pregnancy test
  • Have an implanted defibrillator or pacemaker
  • Current alcohol or substance use judged by the investigator to potentially interfere with study compliance
  • A history of within the past 5 years (prior to screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma.
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1 Visit
  • Individuals receiving ongoing therapy with any of the medications not to be used with FTC, TAF, TDF or other antiretroviral third agents.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
668 participants (actual)

Study arms

  • Experimental
    F/TAF + 3rd Agent

    Participants will receive F/TAF (200/25 mg or 200/10 mg) plus FTC/TDF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks. Dosing of F/TAF will be dependent on the third agent of the participants' pre-existing treatment regimen.

    Drug: F/TAF · Drug: Allowed third antiretroviral agent · Drug: FTC/TDF Placebo

  • Active comparator
    FTC/TDF + 3rd Agent

    Participants will receive FTC/TDF plus F/TAF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks.

    Drug: FTC/TDF · Drug: Allowed third antiretroviral agent · Drug: F/TAF Placebo

Interventions

  • DrugFTC/TDF

    200/300 mg FDC tablets administered orally once daily

    Also known as: Truvada®

  • DrugF/TAF

    Drug pages: Emtricitabine · Tenofovir alafenamide

    Tablets administered orally once daily

    Also known as: Descovy®

  • DrugAllowed third antiretroviral agent

    An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).

  • DrugFTC/TDF Placebo

    Tablets administered orally once daily

  • DrugF/TAF Placebo

    Tablets administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

Secondary outcomes

  1. Percentage Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

    Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.

    Time frame: Baseline; Week 48

  2. Percentage Change From Baseline in Spine BMD at Week 48

    Spine BMD was assessed by DXA scan.

    Time frame: Baseline; Week 48

  3. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  4. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

  5. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the FDA Snapshot Analysis

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  6. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 as Defined by the FDA Snapshot Analysis

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  7. Percentage Change From Baseline in Hip BMD at Week 96

    Hip BMD was assessed by DXA scan.

    Time frame: Baseline; Week 96

  8. Percentage Change From Baseline in Spine BMD at Week 96

    Spine BMD was assessed by DXA scan.

    Time frame: Baseline; Week 96

  9. Change From Baseline in CD4+ Cell Count at Week 96

    Time frame: Baseline; Week 96

07

Results

Posted Nov 30, 2016
Limitations and caveats
There were no limitations affecting the analysis or results.

Participant flow

Participants were enrolled at study sites in North America and Europe. The first participant was screened on 06 May 2014. The last study visit occurred on 1 March 2019.

Double-Blind Phase
Participant flow — Double-Blind Phase
MilestoneF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Started334334
Safety analysis set333330
Completed296300
Not completed3834
Withdrew: Randomized but never treated14
Withdrew: Withdrawal by subject1916
Withdrew: Lost to follow-up74
Withdrew: Physician decision25
Withdrew: Adverse event50
Withdrew: Non-compliance with study drug31
Withdrew: Protocol violation03
Withdrew: Death11
Open-Label Phase
Participant flow — Open-Label Phase
MilestoneF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Started3331
Completed2121
Not completed1210
Withdrew: Physician decision88
Withdrew: Withdrawal by subject32
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis
percentage of participantsF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis94.393.0
Statistical analysis
  • F/TAF + 3rd Agent vs FTC/TDF + 3rd Agent · Cochran-Mantel-Haenszel · p = 0.5 · Percentage difference: 1.3 · 95.002% CI -2.5 to 5.1Difference in percentages of virologic success between treatment groups and its 95.002% CI were calculated based on the Mantel-Haenszel (MH) proportions adjusted by the third agent stratum.
SecondaryPercentage Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.

Time frame:
Baseline; Week 48
Reported as:
Mean · percentage change
Percentage Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
percentage changeF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Percentage Change From Baseline in Hip Bone Mineral Density (BMD) at Week 481.236 ± 2.6602-0.071 ± 2.3316
SecondaryPercentage Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan.

Time frame:
Baseline; Week 48
Reported as:
Mean · percentage change
Percentage Change From Baseline in Spine BMD at Week 48
percentage changeF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Percentage Change From Baseline in Spine BMD at Week 481.662 ± 3.1279-0.109 ± 3.3476
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis
percentage of participantsF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis91.690.9
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ Cell Count at Week 48
cells/μLF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Change From Baseline in CD4+ Cell Count at Week 4820 ± 161.821 ± 152.7
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the FDA Snapshot Analysis

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the FDA Snapshot Analysis
percentage of participantsF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the FDA Snapshot Analysis83.586.1
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 as Defined by the FDA Snapshot Analysis

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 as Defined by the FDA Snapshot Analysis
percentage of participantsF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 as Defined by the FDA Snapshot Analysis88.689.1
SecondaryPercentage Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan.

Time frame:
Baseline; Week 96
Reported as:
Mean · percentage change
Percentage Change From Baseline in Hip BMD at Week 96
percentage changeF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Percentage Change From Baseline in Hip BMD at Week 961.856 ± 3.2195-0.289 ± 2.9912
SecondaryPercentage Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan.

Time frame:
Baseline; Week 96
Reported as:
Mean · percentage change
Percentage Change From Baseline in Spine BMD at Week 96
percentage changeF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Percentage Change From Baseline in Spine BMD at Week 962.159 ± 3.8374-0.109 ± 3.6738
SecondaryChange From Baseline in CD4+ Cell Count at Week 96
Time frame:
Baseline; Week 96
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ Cell Count at Week 96
cells/μLF/TAF + 3rd AgentFTC/TDF + 3rd Agent
Change From Baseline in CD4+ Cell Count at Week 9650 ± 198.746 ± 169.4

Adverse events

Collected over First dose of study drug to the last dose (maximum: 227.4 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
F/TAF + 3rd Agent (Double-Blind)2/333 (0.6%)29/333 (8.7%)242/333 (72.7%)
FTC/TDF + 3rd Agent (Double-Blind)1/330 (0.3%)31/330 (9.4%)226/330 (68.5%)
Open-Label F/TAF From F/TAF0/33 (0%)2/33 (6.1%)12/33 (36.4%)
Open-Label F/TAF From FTC/TDF0/31 (0%)3/31 (9.7%)13/31 (41.9%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventF/TAF + 3rd Agent (Double-Blind)FTC/TDF + 3rd Agent (Double-Blind)Open-Label F/TAF From F/TAFOpen-Label F/TAF From FTC/TDF
Myocardial infarctionCardiac disorders0/3330/3300/331/31
Enteritis infectiousInfections and infestations0/3330/3300/331/31
ArthralgiaMusculoskeletal and connective tissue disorders0/3330/3300/331/31
ArthritisMusculoskeletal and connective tissue disorders0/3330/3300/331/31
Chest painGeneral disorders2/3331/3301/330/31
InfluenzaInfections and infestations0/3330/3301/330/31
LaryngitisInfections and infestations0/3330/3301/330/31
Lung infectionInfections and infestations0/3330/3301/330/31
Prostatitis Escherichia coliInfections and infestations0/3330/3301/330/31
DeliriumPsychiatric disorders0/3330/3301/330/31
Most frequent other events
Showing 10 of 23
Most frequent other events
EventF/TAF + 3rd Agent (Double-Blind)FTC/TDF + 3rd Agent (Double-Blind)Open-Label F/TAF From F/TAFOpen-Label F/TAF From FTC/TDF
Upper respiratory tract infectionInfections and infestations54/33367/3301/330/31
DiarrhoeaGastrointestinal disorders44/33342/3301/330/31
NasopharyngitisInfections and infestations43/33327/3304/332/31
Back painMusculoskeletal and connective tissue disorders37/33328/3303/332/31
CoughRespiratory, thoracic and mediastinal disorders37/33320/3302/332/31
ArthralgiaMusculoskeletal and connective tissue disorders35/33323/3300/332/31
HeadacheNervous system disorders33/33322/3300/331/31
OnychomycosisInfections and infestations6/3333/3300/333/31
SinusitisInfections and infestations23/33328/3302/333/31
BronchitisInfections and infestations32/33326/3301/331/31

Baseline characteristics

The Safety Analysis Set included all randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)F/TAF + 3rd AgentFTC/TDF + 3rd AgentTotal
Mean47 ± 9.948 ± 9.748 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)F/TAF + 3rd AgentFTC/TDF + 3rd AgentTotal
Female4854102
Male285276561
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)F/TAF + 3rd AgentFTC/TDF + 3rd AgentTotal
Hispanic or Latino4878126
Not Hispanic or Latino285252537
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)F/TAF + 3rd AgentFTC/TDF + 3rd AgentTotal
American Indian or Alaska Native213
Asian606
Black6967136
Native Hawaiian or Pacific Islander213
White244253497
Not Permitted112
Other9716
Region of Enrollment
Region of Enrollment(participants)F/TAF + 3rd AgentFTC/TDF + 3rd AgentTotal
Canada5914
Belgium336
United States282274556
Italy268
United Kingdom231740
France182139
Baseline Third Agent
Baseline Third Agent(participants)F/TAF + 3rd AgentFTC/TDF + 3rd AgentTotal
Atazanavir boosted with ritonavir (ATV/r)5350103
Darunavir boosted with ritonavir (DRV/r)8482166
Lopinavir boosted with ritonavir (LPV/r)181836
Dolutegravir (DTG)262349
Efavirenz (EFV)8614
Maraviroc (MVC)167
Nevirapine (NVP)7466140
Raltegravir (RAL)6673139
Rilpivirine (RPV)369
HIV-1 RNA Categories
HIV-1 RNA Categories(participants)F/TAF + 3rd AgentFTC/TDF + 3rd AgentTotal
< 50 copies/mL329326655
>= 50 copies/mL448
CD4 Cell Count
CD4 Cell Count(cells/µL)F/TAF + 3rd AgentFTC/TDF + 3rd AgentTotal
Mean691 ± 272.6667 ± 272.3679 ± 272.5
08

Study locations

78 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Spectrum Medical Group
    Phoenix, Arizona 85012, United States
  • Pacific Oaks Medical Group
    Beverly Hills, California 90211, United States
  • Kaiser Permanente
    Hayward, California 94545, United States
  • Tarrant County ID Associates
    Los Angeles, California 90036, United States
  • Southern California Men's Medical Group
    Los Angeles, California 90069, United States
  • Highland Hospital - Alameda Health System (formerly Alameda County medical Center)
    Oakland, California 94602, United States
  • Kaiser Permanente Sacramento Medical Center
    Sacramento, California 95825, United States
  • La Playa Medical Group and Clinical Research
    San Diego, California 92103, United States
  • Kaiser Permanente Medical Group San Francisco
    San Francisco, California 94118, United States
  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Kaiser Permanente Colorado
    Denver, Colorado 80205, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Apex Research LLC
    Denver, Colorado 80209, United States
  • Dupont Circle Physician's Group
    Washington, District of Columbia 20009, United States
  • Whitman-Walker Health
    Washington, District of Columbia 20009, United States
  • Capital Medical Associates
    Washington, District of Columbia 20036, United States
  • Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • TheraFirst Medical Center
    Fort Lauderdale, Florida 33308, United States
  • Gary J. Richmond,M.D.,P.A.
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • AIDS Healthcare Foundation
    Miami Beach, Florida 33139, United States
  • Tarrant County Infectious Disease Associates
    Miami, Florida 33133, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • AIDS Healthcare Foundation
    Tampa, Florida 33602, United States
  • AIDS Research & Treatment Center of the Treasure Coast
    Vero Beach, Florida 32960, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida 33401, United States
  • Atlanta ID Group
    Atlanta, Georgia 30309, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30312, United States
  • Mercer University School of Medicine
    Macon, Georgia 31201, United States
  • Community Research Initiative of New England
    Boston, Massachusetts 02111, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • The Kc Care Clinic Site 5580
    Kansas City, Missouri 64111, United States
  • St. Louis University
    Saint Louis, Missouri 63110, United States
  • Southampton Healthcare, Inc.
    Saint Louis, Missouri 63139, United States
  • Prime Healthcare Services - St Michael's LLC d/b/a Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
  • Southwest CARE Center
    Santa Fe, New Mexico 87505, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • New York Hospital Queens
    Flushing, New York 11355, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • Ricky K. Hsu, MD, PC
    New York, New York 10011, United States
  • Infectious Disease Consultants, PA
    Charlotte, North Carolina 28209, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • AIDS Arms, Inc
    Dallas, Texas 75215, United States
  • Southwest Infectious Disease Clinical Research, Inc
    Dallas, Texas 75219, United States
  • North Texas Infectious Diseases Consulants
    Dallas, Texas 75246, United States
  • AIDS Arms, Inc./Trinity Health & Wellness Center
    Fort Worth, Texas 76104, United States
  • Therapeutic Concepts, PA
    Houston, Texas 77004, United States
  • Gordon E. Crofoot MD PA
    Houston, Texas 77098, United States
  • Peter Shalit, MD
    Seattle, Washington 98104, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • CHU Saint-Pierre of Brussels
    Brussels, 1000, Belgium
  • Vancouver Infectious Disease Research and Care Centre
    Vancouver, British Columbia V6Z 2C7, Canada
  • Ottawa Hospital-General Campus
    Ottawa, Ontario K1Y 4E9, Canada
  • Maple Leaf Medical Clinic/Maple Leaf Research
    Toronto, Ontario M5B 1L6, Canada
  • University Health Network/Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • University Hospital of Montpellier (CHU-Gui de Chauliac)
    Montpellier, 34295, France
  • CHU de Nantes Hopital de l'Hotel Dieu
    Nantes, 44093, France
  • Hopital Bichat Claude Bernard
    Paris, 75018, France
  • Hôpital Tenon
    Paris, 75020, France
  • Centre Hospitalier de Tourcoing
    Tourcoing, 59208, France
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • IRCCS Ospedale San Raffaele, Centro San Luigi
    Milano, 20127, Italy
  • Hope Clinical Research
    San Juan, 00901, Puerto Rico
  • Clinical Research Puerto Rico Inc
    San Juan, 00909, Puerto Rico
  • University of Puerto Rico School of Medicine
    San Juan, 00935, Puerto Rico
  • Brighton and Sussex University Hospitals
    Brighton, BN2 1ES, United Kingdom
  • Barts Health NHS Trust
    London, E1 1BB, United Kingdom
  • Royal Free London NHS Foundation Trust
    London, NW3 2QG, United Kingdom
  • King's College Hospital
    London, SE5 9RJ, United Kingdom
  • Chelsea and Westminster Hospital
    London, SW10 9TH, United Kingdom
  • Manchester Centre for Sexual Health
    Manchester, M13 0FH, United Kingdom
09

References and documents

Publications

  • Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, Johnson M, Clumeck N, Osiyemi O, Ward D, Morales-Ramirez J, Yan M, Abram ME, Plummer A, Cheng AK, Rhee MS. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016 Apr;3(4):e158-65. doi: 10.1016/S2352-3018(16)00024-2. Epub 2016 Mar 14. PubMed 27036991 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Aug 2015, 15 months.

Results were first posted in Nov 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2014
First posted
Apr 24, 2014
StartActual
May 6, 2014
Primary completionActual
Aug 12, 2015
CompletionActual
Mar 1, 2019
Results first posted
Nov 30, 2016
Last update
Mar 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02121795
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 24, 2014
Start date
May 6, 2014
Primary completion
Aug 12, 2015
Completion
Mar 1, 2019
Results posted
Nov 30, 2016
Last update
Mar 12, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Emtricitabine · Tenofovir alafenamide

Start the discussion